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Abstract
Introduction Meta-analysis is the cornerstone of robust biomedical evidence.
Objectives We investigated whether statistical reporting practices facilitate metabolomics meta-analyses.
Methods A literature review of 44 studies that used a comparable platform.
Results Non-numeric formats were used in 31 studies. In half of the studies,  less than a third of all measures were 
reported. Unadjusted P-values were missing from 12 studies and exact P-values from 9 studies.
Conclusion  Reporting practices can be improved. We recommend (i) publishing all results as numbers, (ii) reporting effect 
sizes of all measured metabolites and (iii) always reporting unadjusted exact P-values.
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1 Introduction
Research data can be shared at multiple levels, as raw 
measurements (e.g. NMR or MS spectra of blood or urine 
samples), as pre-processed intermediate results (metabolite 
concentrations for each individual) or as summary statis-
tics (aggregate associations between metabolites and dis-
eases). For raw data, the diversity of analytical workflows 
is a challenge and we refer to the comprehensive review by 
the COMETS consortium for further information (Playdon 
et al. 2019). For metabolic concentrations from individuals, 
legal and ethical commitments may make sharing difficult in 
human studies. Consequently, meta-analysis of summary sta-
tistics is a common approach in biomedical research. Here, 
we focus on the statistical reporting with special emphasis 
on facilitating meta-analyses.
We investigated the reporting practices of 1H NMR 
metabolomics data from a single high-throughput platform 
(Soininen et al. 2009). The pipeline is built on a highly 
standardized experimental setup that yields over 200 lipid 
and metabolite measures from human serum samples. Every 
researcher receives an identical data spreadsheet. For this 
reason, the differences in reporting are due to the choices 
of the authors without being confounded by the technical 
properties of the analytical platform.
We report findings on the coverage and type of statistics 
reported in 44 different peer-reviewed papers published in 
high-quality journals. As metabolomics data are expand-
ing rapidly in clinical and epidemiological studies, we 
expect our results to help people ensure that the wealth of 
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knowledge can be replicated and re-used effectively and in 
an unbiased manner.
2  Materials and methods
We conducted a literature search for all peer-reviewed arti-
cles that reported results from a single NMR metabolomics 
platform (Soininen et al. 2009) between January 2011 and 
August 2016. Publication lists were obtained from PubMed 
using all three main platform authors as keywords (‘Kangas 
AJ’ and ‘Soininen P’ and ‘Ala-Korpela M’). During the time 
period, these authors were always included in papers that 
used the NMR data as a standard practice. The initial pool 
contained 71 publications. Figure 1a describes the selection 
process of eligible studies from the initial pool. A total of 
44 papers were included for further analyses (Supplement 
Table S1).
We extracted the list of metabolites that were routinely 
reported to all end-users, and the types of summary statistics 
that were available for each metabolite from the publica-
tions. To assess the number of reported metabolites, we then 
chose the type of statistic that covered the largest number 
of metabolites as the primary profile. If multiple profiles 
covered the largest number of metabolites, we preferred 
interventional over longitudinal and over cross-sectional 
profiles. If there were still multiple possible primary pro-
files, we chose the primary profile that was generated from 
a larger sample size.
The NMR metabolomics platform comprised three 
“molecular windows” for (i) lipoprotein subclasses, (ii) 
low-molecular weight metabolites in an intact serum sam-
ple, and (iii) the composition of lipid species after chemi-
cal lipid extraction from the same sample (Soininen et al. 
2009; Würtz et al. 2017). The first two windows were always 
included, whereas the third window of lipid species was 
optional. Small modifications were made between 2011 and 
2016 to the platform affecting the number of reported metab-
olites. The latest version (Würtz et al. 2017) included 228 
metabolite measurements. The lipoprotein measures covered 
14 subclasses and each subclass was reported as concentra-
tions and as a percentage of total lipids. We did not make a 
distinction between concentration or percentage—either was 
a sufficient indicator of availability and only counted once 
if both were available. Therefore, we counted the presence 
of 158 distinct metabolite measures. An earlier version of 
the platform (Inouye et al. 2010) also reported 14 measures 
that were altered or replaced in later versions. Altogether, 
we created a master list of 172 metabolite measurements.
3  Results and discussion
We included 44 studies, of which 21 we classified as cross-
sectional designs, 12 as cross-sectional designs with a lon-
gitudinal clinical endpoint (NMR analysis was performed 
at baseline only) and 11 as longitudinal studies with at least 
two NMR measurements. The median number of partici-
pants was 738 (IQR 3537; min 12; max 10,083). We found 
24 different cohorts in the 44 studies. Most of the cohorts 
were from Finland (19 cohorts) and five were from Europe. 
All but two studies included both men and women. Most 
papers were under an open access scheme (35 out of 44). We 
identified three important issues: (i) non-numerical result 
formats, (ii) selective reporting of a few metabolites instead 
of the full profile and (iii) different indicators for statistical 
evidence between studies.
Regarding the result format, we found that only 13 out of 
44 primary profiles were included in a spreadsheet or a text 
document in such a form that the results could be easily con-
verted to numbers. Usually, the results were either embedded 
in the main text (24 out of 44) or as a PDF supplement (7 out 
of 44). Six studies published their primary profile in a figure. 
Non-numeric results formats can cause technical problems 
and typing errors if the values cannot be copied directly or 
read in by a machine interface.
Most of the results presented measurements for a sub-
set of metabolites only. The median number of measures 
reported was 36 (IQR 44), which was substantially fewer 
than the maximum of 172 in the master list. This means that 
incomplete profiles were the norm rather than the exception 
(Fig. 1b–d). Selective reporting may prevent the re-use of 
summary statistics. From a meta-analysis perspective, it is 
critical to report metabolites that are not showing a statisti-
cally significant signal, as they will contribute to the overall 
meta-statistic. Furthermore, it is difficult for readers to assess 
the role of multiple testing if only a subset of metabolic data 
is reported (presumably the authors would have screened all 
the measures since they are delivered in a single Excel file). 
There is a great temptation to break a single metabolomics 
study into several manuscripts to boost publication records, 
however, such practice may not fit well with the nature of 
omics data and systems-based interpretation.
The choice for a descriptive statistic depends on the study 
design and whether the outcome is continuous or categori-
cal. Therefore, it is challenging for all studies to use the 
same statistical test. Of note, 9 out of the 44 publications 
reported means and standard deviations, 1 profile reported 
means only, 3 reported mean differences, 1 reported medi-
ans, 9 focused on regression coefficients, 6 reported cor-
relation coefficients, 8 reported either hazard or odds ratios, 
2 studies reported percentage changes, 2 reported changes 
normalized by standard deviations, 1 study reported P-values 
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(of correlation coefficients) only, 1 profile reported the per-
centage change with respect to the interquartile range and 
1 profile reported the area under the curve. Therefore, the 
descriptive statistics were diverse, which made it difficult to 
assign mutually comparable effect sizes in meta-analysis and 
other integrative settings.
Regardless of the descriptive statistic, the P value is 
universally comparable between studies, which makes 
it an appealing report item for integrative analyses. Two 
publications out of 44 did not include P-values or confidence 
intervals for the primary profile, 3 reported confidence inter-
vals only and 4 papers reported only thresholds for P-values. 
In several studies, adjustments for multiple testing were con-
ducted. Bonferroni adjustment or its variants were applied 
in 22 papers and 6 papers used the false discovery rate (one 
study used both adjustments). Both unadjusted and adjusted 
P-values were reported for 24 profiles. Unadjusted P-val-
ues were reported exclusively for 8 profiles, and adjusted 
a b
c
d
Fig. 1  Selection criteria for publications that were included in the 
analysis (a) and the binary heatmap of available summary statistics 
from 44 research papers organized by the type of experiment (b–d). 
Each column represents a paper and each row shows the availability 
of summary statistics for a metabolic measure. The results for the 
lipoprotein window (b), lipid window (c) and low-molecular weight 
molecules window (d) are shown
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P-values exclusively for 3 profiles. The unadjusted P-value 
is preferred here as there are multiple existing methods 
to combine P-values from multiple datasets (Blettner and 
Schlattmann, 2005). Also, P-values should be reported as 
exact numbers when possible rather than providing an upper 
limit (i.e. P < 0.05 should be reported as P = 0.0034).
Most study cohorts were from Finland, which means that 
our source material had limited global coverage. But the 
articles were published in the top peer-reviewed interna-
tional journals within their target disciplines and the authors 
included leading international experts in epidemiology and 
medicine. For this reason, our results are likely to reflect 
the reporting practices in metabolomics studies of human 
cohorts in general.
We investigated how metabolomics data were reported 
within a subset of papers that used the same NMR metabo-
lomics platform. Importantly, the restricted scope enabled us 
to focus on the reporting of the results without confounding 
from technological changes. In summary, we observed a lack 
of consistency on how the results were reported, which had 
a negative impact on our ability to re-use the summary sta-
tistics for integrative analyses. We recommend the authors 
of future studies to report both the unadjusted P-value and 
the effect size regarding the primary outcome for all metabo-
lites, and to include these results as a separate spreadsheet 
supplement if the journal policy allows it.
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